Intravenous Ciprofloxacin for the Treatment of Lower Respiratory Tract Infections: Preliminary Results

  • P. Mangiarotti
  • C. Grassi
Conference paper


Ciprofloxacin has favorable pharmacokinetic characteristics and good antibacterial activity against most respiratory bacterial pathogens. This allows an effective use of ciprofloxacin in bacterial respiratory tract infections [1]. The availability of a drag in both intravenous and oral formulations may allow physicians to prescribe a sequential treatment in which an initial parenteral attack phase is followed by an oral consolidation phase after a few days of clinical improvement. Studies so far performed have demonstrated that in various serious infections oral ciprofloxacin can shorten the course of parenteral antibiotics and thus minimize the period of hospitalization and reduce costs [2–6].


Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Patient Lower Respiratory Tract Infection Eradication Rate Klebsiella Oxytoca 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Campoli-Richards DM, Monk JP, Price A, Benfield P, Ward A (1988) Ciprofloxacin, a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35:373–447PubMedCrossRefGoogle Scholar
  2. 2.
    Khan FA, Basir R (1989) Sequential intravenous-oral administration of ciprofloxacin vs. ceftazidime in serious bacterial respiratory tract infections. Chest 96:528–537Google Scholar
  3. 3.
    Menon L, Ernst JA, Sy ER, Flores D, Pacia A, Lorian V (1989) Brief report: sequential intravenous/oral ciprofloxacin compared with intravenous ceftazidime in the treatment of serious lower respiratory tract infections. Am J Med 87 [Suppl 5A]:119–120CrossRefGoogle Scholar
  4. 4.
    Thys JP, Jacobs F, Motte S (1989) Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis 11 [Suppl 5]: 15–22CrossRefGoogle Scholar
  5. 5.
    Costas J, Chrysantopoulos CJ, Skoutelis AT, Bassaris HP (1993) Shortened hospital stay with sequential intravenous/oral ciprofloxacin. Drugs 45 [Suppl]:75Google Scholar
  6. 6.
    Paladino JA, Cumbo TJ, Schentag JJ, Bloom MJ, Serrianne DJ, Burnett GJ (1993) Abbreviating the duration of intravenous antibiotics with oral fluoroquinolones. Drugs 45 [Suppl]:77Google Scholar
  7. 7.
    Paladino JA, Van Slooten A (1993) Economic impact of IV and IV-to-PO sequential ciprofloxacin vs. standard IV antibiotics. Drugs 45 [Suppl]:76Google Scholar
  8. 8.
    Lode H, Wiley E, Olschewski P et al. (1990) Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections. Scand J Infect Dis 68 [Suppl]:50–55Google Scholar
  9. 9.
    Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC, Levin S (1989) Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 87 [Suppl 5A]:116–118CrossRefGoogle Scholar
  10. 10.
    Mangiarotti P, Bertoletti R, Grassi G, Piccioni P, Grassi FA, Gialdroni Grassi G (1990) Possibilità di trattamento a breve termine delle infezioni respiratorie. J Chemother 2 [Suppl]:68–73Google Scholar
  11. 11.
    Mangiarotti P, Bianchi L, Mazzola G, Meloni F, Ballabio PC, Gialdroni Grassi G (1992) Effect of multiple low dose regimen of ciprofloxacin on steady state theophylline serum concentrations. 8th Mediterranean Congress of Chemotherapy, Athens 24–29 May, abstract no 657Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. Mangiarotti
  • C. Grassi

There are no affiliations available

Personalised recommendations